Literature DB >> 22929816

Clopidogrel resistance - a clear problem with an unclear solution.

Sameer Bansilal, Deepak L Bhatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22929816      PMCID： PMC3861305          DOI： 10.1016/j.ihj.2012.06.002

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


× No keyword cloud information.
  23 in total

1.  Variability in platelet responsiveness to clopidogrel among 544 individuals.

Authors:  Victor L Serebruany; Steven R Steinhubl; Peter B Berger; Alex I Malinin; Deepak L Bhatt; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

2.  The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.

Authors:  Deepak L Bhatt; Guillaume Paré; John W Eikelboom; Katy L Simonsen; Eileen S Emison; Keith A A Fox; Ph Gabriel Steg; Gilles Montalescot; Nihar Bhakta; Werner Hacke; Marcus D Flather; Koon-Hou Mak; Patrice Cacoub; Mark A Creager; Peter B Berger; Steven R Steinhubl; Gurunathan Murugesan; Shamir R Mehta; Kandice Kottke-Marchant; A Michael Lincoff; Eric J Topol
Journal:  Eur Heart J       Date:  2012-03-26       Impact factor: 29.983

3.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

4.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Authors:  Dietmar Trenk; Willibald Hochholzer; Martin F Fromm; Ligia-Emilia Chialda; Andreas Pahl; Christian M Valina; Christian Stratz; Peter Schmiebusch; Hans-Peter Bestehorn; Heinz Joachim Büttner; Franz-Josef Neumann
Journal:  J Am Coll Cardiol       Date:  2008-05-20       Impact factor: 24.094

5.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

6.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

7.  Genetic determinants of response to clopidogrel and cardiovascular events.

Authors:  Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

9.  Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.

Authors:  Thomas J Helton; Anthony A Bavry; Dharam J Kumbhani; Sandeep Duggal; Henri Roukoz; Deepak L Bhatt
Journal:  Am J Cardiovasc Drugs       Date:  2007       Impact factor: 3.571

10.  Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

Authors:  Dirk Sibbing; Julia Stegherr; Wolfgang Latz; Werner Koch; Julinda Mehilli; Katharina Dörrler; Tanja Morath; Albert Schömig; Adnan Kastrati; Nicolas von Beckerath
Journal:  Eur Heart J       Date:  2009-02-04       Impact factor: 29.983
View more
  1 in total

Review 1.  A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease.

Authors:  Zhaojian Zhang; Yu Wang; Wangxiao Tan; Siwei Wang; Jinghua Liu; Xiao Liu; Xiaoying Wang; Xiumei Gao
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-19       Impact factor: 2.629
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.